O-Dealkylation of Fluoxetine in Relation toCYP2C19 Gene Dose and Involvement of CYP3A4 in Human Liver Microsomes
- Zhao-Qian Liu,
- Bing Zhu,
- Yun-Fu Tan,
- Zhi-Rong Tan,
- Lian-Sheng Wang,
- Song-Lin Huang,
- Yan Shu1 and
- Hong-Hao Zhou
- Pharmacogenetics Research Institute, Xiang-Ya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China
- Prof. Hong-Hao Zhou, Pharmacogenetics Research Institute, Xiang-Ya School of Medicine, Central South University, Changsha, Hunan 410078, P. R. China. E-mail: hhzhou{at}public.cs.hn.cn
Abstract
This work evaluated the kinetic behavior of fluoxetineO-dealkylation in human liver microsomes from differentCYP2C19 genotypes and identified the isoenzymes of cytochrome P450 involved in this metabolic pathway. The kinetics of the ρ-trifluoromethylphenol (TFMP) formation from fluoxetine was determined in human liver microsomes from three homozygous (wt/wt) and three heterozygous (wt/m1) extensive metabolizers (EMs) and three poor metabolizers (PMs) withm1 mutation (m1/m1) with respect to CYP2C19. The formation rate of TFMP was determined by gas chromatograph with electron-capture detection. The kinetics of TFMP formation was best described by the two-enzyme and single-enzyme Michaelis-Menten equation for liver microsomes from CYP2C19 EMs and PMs, respectively. The mean intrinsic clearance (Vmax/Km) for the high- and low-affinity component was 25.2 μl/min/nmol and 3.8 μl/min/nmol of cytochrome P450 in the homozygous EMs microsomes and 12.8 μl/min/nmol and 2.9 μl/min/nmol of cytochrome P450 in the heterozygous EMs microsomes, respectively. Omeprazole (a CYP2C19 substrate) at a high concentration and triacetyloleandomycin (a selective inhibitor of CYP3A4) substantially inhibitedO-dealkylation of fluoxetine. Furthermore, fluoxetineO-dealkylation was correlated significantly withS-mephenytoin 4′-hydroxylation at a low substrate concentration and midazolam 1′-hydroxylation at a high substrate concentration in liver microsomes of 11 Chinese individuals, respectively. Moreover, there were obvious differences in theO-dealkylation of fluoxetine in liver microsomes from different CYP2C19 genotypes and in microsomal fractions of different human-expressed lymphoblast P450s. The results demonstrated that polymorphic CYP2C19 and CYP3A4 enzymes were the major cytochrome P450 isoforms responsible for fluoxetineO-dealkylation, whereas CYP2C19 catalyzed the high-affinity O-dealkylation of fluoxetine, and its contribution to this metabolic reaction was gene dose-dependent.
Footnotes
-
↵1 Current address: Department of Biopharmaceutical Sciences, University of California, San Francisco, CA 94143. E-mail:yans{at}itsa.ucsf.edu
-
This work was supported by China Medical Board of America Grants 92-568 and 99-697.
- Abbreviations:
- CYP
- cytochrome P450
- TFMP
- ρ-trifluoromethylphenol
- DDC
- diethyldithiocarbamate
- EM
- extensive metabolizer
- PM
- poor metabolizer
- GC-ECD
- gas chromatograph with electron-capture detection
- PFBSC
- pentafluorobenzenesulfonyl chloride
- TAO
- triacetyloleandomycin
-
- Received February 6, 2001.
- Accepted August 21, 2001.
- The American Society for Pharmacology and Experimental Therapeutics



